The role of eravacycline in combating multidrug-resistant bacterial infections: insights into efficacy, emerging resistance, and clinical safety.

The global rise of multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus spp (VRE), poses a major public health threat and complicates treatment. Eravacycline, a new synthetic fluorocycline antibiotic, shows strong in vitro effectiveness against various multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria and anaerobes. Its unique structural modifications help it overcome common tetracycline resistance mechanisms. Real-world data show eravacycline achieves high cure and survival rates with low recurrence for infections by CRE, CRAB, MRSA, and VRE, though its effectiveness against Pseudomonas aeruginosa and Burkholderia cepacia is limited. Key resistance mechanisms in clinical isolates include efflux pump upregulation, ribosomal mutations, and plasmid-mediated tet(X) genes. Eravacycline is generally safe, causing fewer gastrointestinal issues than tigecycline and less nephrotoxicity than polymyxins. It doesn't require dosage adjustments for renal or mild-to-moderate hepatic impairment. Eravacycline is vital for treating MDR infections when traditional therapies fail. However, it is currently approved by the U.S. Food and Drug Administration specifically for parenteral administration in the treatment of complicated intra-abdominal infections. Therefore, more large-scale trials are needed to confirm its effectiveness, optimize combination therapies, and further address the MDR crisis.